Martingale Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.29M | Buy |
20,153
+1,101
| +6% | +$125K | 0.06% | 277 |
|
|
2025
Q1 | $2M | Buy |
19,052
+960
| +5% | +$101K | 0.05% | 300 |
|
|
2024
Q4 | $1.94M | Buy |
18,092
+270
| +2% | +$28.9K | 0.05% | 318 |
|
|
2024
Q3 | $1.78M | Sell |
17,822
-2,200
| -11% | -$220K | 0.04% | 341 |
|
|
2024
Q2 | $1.69M | Sell |
20,022
-11,757
| -37% | -$991K | 0.04% | 341 |
|
|
2024
Q1 | $2.32M | Sell |
31,779
-180
| -0.6% | -$13.2K | 0.05% | 265 |
|
|
2023
Q4 | $2.28M | Sell |
31,959
-165
| -0.5% | -$11.8K | 0.05% | 258 |
|
|
2023
Q3 | $1.92M | Buy |
32,124
+3,853
| +14% | +$231K | 0.04% | 274 |
|
|
2023
Q2 | $2.04M | Buy |
28,271
+16,380
| +138% | +$1.18M | 0.04% | 272 |
|
|
2023
Q1 | $875K | Buy |
+11,891
| New | +$875K | 0.02% | 477 |
|
|
2019
Q2 | – | Sell |
-7,055
| Closed | -$554K | – | 1039 |
|
|
2019
Q1 | $554K | Sell |
7,055
-18,596
| -72% | -$1.46M | 0.01% | 875 |
|
|
2018
Q4 | $2.17M | Sell |
25,651
-483
| -2% | -$40.9K | 0.03% | 514 |
|
|
2018
Q3 | $4.48M | Buy |
26,134
+2
| +0% | +$343 | 0.05% | 338 |
|
|
2018
Q2 | $3.38M | Hold |
26,132
| – | – | 0.04% | 412 |
|
|
2018
Q1 | $2.69M | Sell |
26,132
-321
| -1% | -$33.1K | 0.03% | 452 |
|
|
2017
Q4 | $2.26M | Buy |
26,453
+14,269
| +117% | +$1.22M | 0.03% | 503 |
|
|
2017
Q3 | $1.04M | Buy |
+12,184
| New | +$1.04M | 0.01% | 717 |
|
|
2016
Q4 | – | Sell |
-8,336
| Closed | -$531K | – | 989 |
|
|
2016
Q3 | $531K | Buy |
+8,336
| New | +$531K | 0.01% | 800 |
|